{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:45:05Z","timestamp":1794203105132,"version":"4.8.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"am","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019337","name":"Miami Clinical and Translational Science Institute, University of Miami","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006975","name":"Indiana Clinical and Translational Sciences Institute","doi-asserted-by":"publisher","award":["KL2TR002554"],"award-info":[{"award-number":["KL2TR002554"]}],"id":[{"id":"10.13039\/100006975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.eprac.2024.04.018","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T12:46:41Z","timestamp":1714567601000},"page":"663-669","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Racial Disparities in Evidence-Based Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0690-1526","authenticated-orcid":false,"given":"Anastasia-Stefania","family":"Alexopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Parish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maren","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan C.","family":"Batch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Moylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.eprac.2024.04.018_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2024.04.018_bib2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1478-7954-11-18","article-title":"Modeling the impact of prevention policies on future diabetes prevalence in the United States: 2010-2030","volume":"11","author":"Gregg","year":"2013","journal-title":"Popul Health Metr"},{"issue":"4","key":"10.1016\/j.eprac.2024.04.018_bib3","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2024.04.018_bib4","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2337\/dc20-1778","article-title":"High prevalence of advanced liver fibrosis assessed by transient elastography among U.S. Adults with type 2 diabetes","volume":"44","author":"Ciardullo","year":"2021","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2024.04.018_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cld.2017.08.001","article-title":"Clinical and Economic burden of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"22","author":"Younossi","year":"2018","journal-title":"Clin Liver Dis"},{"issue":"2","key":"10.1016\/j.eprac.2024.04.018_bib6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/cld.948","article-title":"Racial disparities in diagnosis and Prognosis of nonalcoholic fatty liver disease","volume":"16","author":"Samji","year":"2020","journal-title":"Clin Liver Dis"},{"issue":"Suppl 1","key":"10.1016\/j.eprac.2024.04.018_bib7","first-page":"S34","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: Standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.eprac.2024.04.018_bib8","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.2337\/dci21-0020","article-title":"Preparing for the NASH epidemic: a call to action","volume":"44","author":"Kanwal","year":"2021","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eprac.2024.04.018_bib9","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/liv.15324","article-title":"Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: an international physician needs assessment","volume":"42","author":"Lazure","year":"2022","journal-title":"Liver Int"},{"issue":"12","key":"10.1016\/j.eprac.2024.04.018_bib10","article-title":"Underrecognition of nonalcoholic fatty liver disease in poorly-controlled diabetes: a call to action in diabetes care","volume":"5","author":"Alexopoulos","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"issue":"11","key":"10.1016\/j.eprac.2024.04.018_bib11","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1080\/17474124.2021.1974295","article-title":"Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review","volume":"15","author":"Schattenberg","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2024.04.018_bib12","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"1","key":"10.1016\/j.eprac.2024.04.018_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.eprac.2024.04.018_bib14","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2024.04.018_bib15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/ajg.2016.453","article-title":"Age as a confounding factor for the accurate non-Invasive diagnosis of advanced NAFLD fibrosis","volume":"112","author":"McPherson","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.eprac.2024.04.018_bib16","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A\u00a0multi-society Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2024.04.018_bib17","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12916-018-1103-x","article-title":"Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease","volume":"16","author":"Alexander","year":"2018","journal-title":"BMC Med"},{"issue":"2","key":"10.1016\/j.eprac.2024.04.018_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.15403\/jgld.2014.1121.252.naf","article-title":"Real-life Perception and practice patterns of NAFLD\/NASH in Romania: results of a survey completed by 102 board-certified Gastroenterologists","volume":"25","author":"Iacob","year":"2016","journal-title":"J\u00a0Gastrointestin Liver Dis"},{"key":"10.1016\/j.eprac.2024.04.018_bib19","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.2147\/JMDH.S367607","article-title":"Differences in NAFLD\/NASH management by provider specialty: Opportunities for Optimizing Multidisciplinary care","volume":"15","author":"Porayko","year":"2022","journal-title":"J\u00a0Multidiscip Healthc"},{"issue":"6","key":"10.1016\/j.eprac.2024.04.018_bib20","doi-asserted-by":"crossref","first-page":"e1456","DOI":"10.1016\/j.cgh.2021.06.048","article-title":"A\u00a0global survey of physicians knowledge about nonalcoholic fatty liver disease","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2024.04.018_bib21","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cgh.2017.09.041","article-title":"Racial and ethnic disparities in nonalcoholic fatty liver disease prevalence, Severity, and outcomes in the United States: a systematic review and meta-analysis","volume":"16","author":"Rich","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2024.04.018_bib22","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S2213-8587(23)00129-8","article-title":"Disparities in diabetes prevalence and management by race and ethnicity in the USA: defining a path forward","volume":"11","author":"Hassan","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.eprac.2024.04.018_bib23","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2023-003763","article-title":"Prescribing of evidence-based diabetes pharmacotherapy in patients with metabolic dysfunction-associated steatohepatitis","volume":"11","author":"Alexopoulos","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"6","key":"10.1016\/j.eprac.2024.04.018_bib24","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S2468-1253(21)00100-X","article-title":"Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA","volume":"6","author":"Rich","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24005081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X24005081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T10:08:25Z","timestamp":1722074905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X24005081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1530891X24005081"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2024.04.018","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Racial Disparities in Evidence-Based Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients With Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2024.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}